U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H21NO2S
Molecular Weight 315.43
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of A-86929

SMILES

CCCC1=CC2=C(CN[C@@H]3CCC4=CC(O)=C(O)C=C4[C@@H]23)S1

InChI

InChIKey=REHAKLRYABHSQJ-KDOFPFPSSA-N
InChI=1S/C18H21NO2S/c1-2-3-11-7-13-17(22-11)9-19-14-5-4-10-6-15(20)16(21)8-12(10)18(13)14/h6-8,14,18-21H,2-5,9H2,1H3/t14-,18+/m1/s1

HIDE SMILES / InChI

Molecular Formula C18H21NO2S
Molecular Weight 315.43
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: http://adisinsight.springer.com/drugs/800006590 | https://www.ncbi.nlm.nih.gov/pubmed/8558425 | https://www.ncbi.nlm.nih.gov/pubmed/10360765

Adrogolide is a chemically stable prodrug of the dopamine D1 receptor agonist A-86929. Adrogolide is rapidly converted in plasma to A-86929. A-86929 has high affinity and functional selectivity for the dopamine D1 receptor. Adrogolide has been in phase II clinical trials for the treatment of Parkinson's disease and cocaine abuse. However, this research has been discontinued. The adverse events associated with its use of adrogolide were of mild-to-moderate severity and included injection site reaction, asthenia, headache, nausea, vomiting, postural hypotension, vasodilitation, and dizziness.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
51.0 nM [Ki]
15.0 nM [Ki]
750.0 nM [Ki]
Conditions
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
19.4 ng/mL
5 mg single, intravenous
dose: 5 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
A-86929 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
19.1 ng/mL
6.6 mg single, respiratory
dose: 6.6 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
A-86929 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
13.6 ng/mL
19.8 mg single, respiratory
dose: 19.8 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
A-86929 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
15.2 ng/mL
3.3 mg 1 times / day single, respiratory
dose: 3.3 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
A-86929 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
24.2 ng/mL
13.2 mg single, respiratory
dose: 13.2 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
A-86929 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
42.7 ng × h/mL
5 mg single, intravenous
dose: 5 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
A-86929 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
16.1 ng × h/mL
6.6 mg single, respiratory
dose: 6.6 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
A-86929 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
22.5 ng × h/mL
19.8 mg single, respiratory
dose: 19.8 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
A-86929 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
10.6 ng × h/L
3.3 mg 1 times / day single, respiratory
dose: 3.3 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
A-86929 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
26 ng × h/mL
13.2 mg single, respiratory
dose: 13.2 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
A-86929 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.3 h
5 mg single, intravenous
dose: 5 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
A-86929 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
3.2 h
6.6 mg single, respiratory
dose: 6.6 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
A-86929 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
5.5 h
19.8 mg single, respiratory
dose: 19.8 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
A-86929 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
3.2 h
3.3 mg 1 times / day single, respiratory
dose: 3.3 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
A-86929 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
3.2 h
13.2 mg single, respiratory
dose: 13.2 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
A-86929 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
20 mg single, intravenous
Studied dose
Dose: 20 mg
Route: intravenous
Route: single
Dose: 20 mg
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Disc. AE: Nausea and vomiting...
Other AEs: injection site reaction, vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea and vomiting (severe, 1 pt)
Other AEs:
injection site reaction (85%)
vomiting (31%)
Nausea (38%)
headache (62%)
Asthenia (62%)
Postural hypotension (31%)
vasodilatation (31%)
Dizziness (31%)
Sources:
40 mg 1 times / day multiple, intravenous
Highest studied dose
Dose: 40 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
Other AEs: headache, Flushing...
Other AEs:
headache
Flushing
Nausea
Injection site reaction
Sources:
AEs

AEs

AESignificanceDosePopulation
Dizziness 31%
20 mg single, intravenous
Studied dose
Dose: 20 mg
Route: intravenous
Route: single
Dose: 20 mg
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Postural hypotension 31%
20 mg single, intravenous
Studied dose
Dose: 20 mg
Route: intravenous
Route: single
Dose: 20 mg
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
vasodilatation 31%
20 mg single, intravenous
Studied dose
Dose: 20 mg
Route: intravenous
Route: single
Dose: 20 mg
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
vomiting 31%
20 mg single, intravenous
Studied dose
Dose: 20 mg
Route: intravenous
Route: single
Dose: 20 mg
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Nausea 38%
20 mg single, intravenous
Studied dose
Dose: 20 mg
Route: intravenous
Route: single
Dose: 20 mg
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Asthenia 62%
20 mg single, intravenous
Studied dose
Dose: 20 mg
Route: intravenous
Route: single
Dose: 20 mg
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
headache 62%
20 mg single, intravenous
Studied dose
Dose: 20 mg
Route: intravenous
Route: single
Dose: 20 mg
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
injection site reaction 85%
20 mg single, intravenous
Studied dose
Dose: 20 mg
Route: intravenous
Route: single
Dose: 20 mg
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Nausea and vomiting severe, 1 pt
Disc. AE
20 mg single, intravenous
Studied dose
Dose: 20 mg
Route: intravenous
Route: single
Dose: 20 mg
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Flushing
40 mg 1 times / day multiple, intravenous
Highest studied dose
Dose: 40 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
Injection site reaction
40 mg 1 times / day multiple, intravenous
Highest studied dose
Dose: 40 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
Nausea
40 mg 1 times / day multiple, intravenous
Highest studied dose
Dose: 40 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
headache
40 mg 1 times / day multiple, intravenous
Highest studied dose
Dose: 40 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

2, 4 mg over a 1-h period immediately prior to cocaine self-administration sessions
Route of Administration: Intravenous
The EC50 value of A-86929 at cloned human dopamine D1 receptors was more than 400 times greater than that observed at the cloned human dopamine D2 receptor, and the potency of A-86929 was nearly 10-fold greater at the human dopamine D5 than at the dopamine D1 receptor.
Substance Class Chemical
Created
by admin
on Tue Apr 01 20:53:23 GMT 2025
Edited
by admin
on Tue Apr 01 20:53:23 GMT 2025
Record UNII
S3ZIH99X6E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
A-86929
Code English
DI-DEACETYL ADROGOLIDE
Preferred Name English
(5AR,11BS)-4,5,5A,6,7,11B-HEXAHYDRO-2-PROPYLBENZO(F)THIENO(2,3-C)QUINOLINE-9,10-DIOL
Systematic Name English
BENZO(F)THIENO(2,3-C)QUINOLINE-9,10-DIOL, 4,5,5A,6,7,11B-HEXAHYDRO-2-PROPYL-, (5AR,11BS)-
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID501028589
Created by admin on Tue Apr 01 20:53:23 GMT 2025 , Edited by admin on Tue Apr 01 20:53:23 GMT 2025
PRIMARY
CAS
171961-95-8
Created by admin on Tue Apr 01 20:53:23 GMT 2025 , Edited by admin on Tue Apr 01 20:53:23 GMT 2025
PRIMARY
WIKIPEDIA
A-86929
Created by admin on Tue Apr 01 20:53:23 GMT 2025 , Edited by admin on Tue Apr 01 20:53:23 GMT 2025
PRIMARY
PUBCHEM
9841398
Created by admin on Tue Apr 01 20:53:23 GMT 2025 , Edited by admin on Tue Apr 01 20:53:23 GMT 2025
PRIMARY
CAS
187661-43-4
Created by admin on Tue Apr 01 20:53:23 GMT 2025 , Edited by admin on Tue Apr 01 20:53:23 GMT 2025
NON-SPECIFIC STEREOCHEMISTRY
FDA UNII
S3ZIH99X6E
Created by admin on Tue Apr 01 20:53:23 GMT 2025 , Edited by admin on Tue Apr 01 20:53:23 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> AGONIST
AGONIST
Ki
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
AGONIST
EC50
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
ACTIVE MOIETY